Literature DB >> 35644526

Association of fetal fraction with hypertensive disorders of pregnancy incidence and disease severity.

Raj Shree1, Teodora R Kolarova2, Hayley J MacKinnon2, Christina M Lockwood3, Suchitra Chandrasekaran4.   

Abstract

BACKGROUND: Hypertensive disorders of pregnancy contribute to maternal and offspring morbidity and mortality. Studies suggest that a lower early pregnancy fetal fraction is associated with an increased risk of hypertensive disorders of pregnancy. However, maternal obesity significantly affects fetal fraction and is a risk factor for hypertensive disorders of pregnancy.
OBJECTIVE: We determined the association between fetal fraction (using a standardized single-institution platform, including male and female fetuses) and hypertensive disorders of pregnancy, stratified by obesity status. Second, we evaluated differences in total cell-free DNA concentration and correlation of fetal fraction with clinical markers of hypertensive disorders of pregnancy severity. STUDY
DESIGN: This was a retrospective, single-institution study of a previously validated cell-free DNA-based noninvasive prenatal screening assay of 1058 samples. Maternal body mass index at the time of noninvasive prenatal screening was assessed, and hypertensive disorders of pregnancy were confirmed by a detailed medical record review. Differences in fetal fraction and total cell-free DNA concentration between the groups were assessed with univariate analyses. Multivariable regression was used to evaluate the association between fetal fraction and hypertensive disorders of pregnancy, adjusted for body mass index, maternal age, gestational age at noninvasive prenatal screening, and fetal sex. The association between fetal fraction and hypertensive disorders of pregnancy among individuals with obesity (body mass index, ≥30 kg/m2) and individuals without obesity (body mass index, <30 kg/m2) was investigated while controlling for the aforementioned covariates. Lastly, multivariable linear regression was used to evaluate the association between fetal fraction and clinical markers of hypertensive disorders of pregnancy severity.
RESULTS: We identified individuals with (n=117) and without (n=941) hypertensive disorders of pregnancy with noninvasive prenatal screening drawn before 20 weeks of gestation and with fetal fraction and body mass index data available. Those with hypertensive disorders of pregnancy had a lower fetal fraction (10.2%±4.2% vs 11.6%±4.7%; P<.01), without differences in total cell-free DNA concentration (P=.14). When groups were stratified by obesity status, this relationship was only valid for individuals without obesity (P=.02). Only when logistic regression analysis was restricted to individuals without obesity did the likelihood of hypertensive disorders of pregnancy rise with decreasing fetal fraction (odds ratio, 0.93; 95% confidence interval, 0.88-0.99; P=.02). In addition, fetal fraction was inversely associated with maximum systolic blood pressure at the time of hypertensive disorders of pregnancy only in the population without obesity (β, -0.08; 95% confidence interval, -0.147 to -0.01; P=.02).
CONCLUSION: Although a lower fetal fraction is associated with the development of hypertensive disorders of pregnancy, the use of this parameter for the prediction may be problematic in individuals with obesity, as obesity has such a profound effect on fetal fraction. However, we uniquely noted that among individuals without obesity, fetal fraction is lower for those that develop hypertensive disorders of pregnancy and lower fetal fraction increases the odds of hypertensive disorders of pregnancy development. Lastly, low fetal fraction in the population without obesity that developed hypertensive disorders of pregnancy was associated with higher systolic blood pressure at the time of hypertensive disorders of pregnancy, an important clinical marker of hypertensive disorders of pregnancy severity. As analytical approaches of cell-free DNA interrogation advance, the prediction of placental-mediated disorders with first-trimester sampling is likely to improve, although this may remain challenging in gravidas with obesity, a cohort at high risk of developing hypertensive disorders of pregnancy.
Copyright © 2022 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  cell-free DNA; fetal fraction; hypertensive disorders of pregnancy; obesity; preeclampsia

Mesh:

Substances:

Year:  2022        PMID: 35644526      PMCID: PMC9452472          DOI: 10.1016/j.ajogmf.2022.100671

Source DB:  PubMed          Journal:  Am J Obstet Gynecol MFM        ISSN: 2589-9333


  40 in total

Review 1.  Fetal DNA in maternal plasma: biology and diagnostic applications.

Authors:  Y M Lo
Journal:  Clin Chem       Date:  2000-12       Impact factor: 8.327

2.  The influence of low molecular weight heparin medication on plasma DNA in pregnant women.

Authors:  Sebastian Grömminger; Sanli Erkan; Ulrike Schöck; Kerstin Stangier; Joachim Bonnet; Rüdiger Schloo; Angela Schubert; Eva-Christina Prott; Ute Knoll; Markus Stumm; Christof von Kalle; Wera Hofmann
Journal:  Prenat Diagn       Date:  2015-09-04       Impact factor: 3.050

3.  Association between fetal fraction on cell-free DNA testing and first-trimester markers for pre-eclampsia.

Authors:  D L Rolnik; F da Silva Costa; T J Lee; M Schmid; A C McLennan
Journal:  Ultrasound Obstet Gynecol       Date:  2018-10-26       Impact factor: 7.299

4.  Analysis of cell-free DNA in maternal blood in screening for aneuploidies: meta-analysis.

Authors:  M M Gil; R Akolekar; M S Quezada; B Bregant; K H Nicolaides
Journal:  Fetal Diagn Ther       Date:  2014       Impact factor: 2.587

5.  Size-based molecular diagnostics using plasma DNA for noninvasive prenatal testing.

Authors:  Stephanie C Y Yu; K C Allen Chan; Yama W L Zheng; Peiyong Jiang; Gary J W Liao; Hao Sun; Ranjit Akolekar; Tak Y Leung; Attie T J I Go; John M G van Vugt; Ryoko Minekawa; Cees B M Oudejans; Kypros H Nicolaides; Rossa W K Chiu; Y M Dennis Lo
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-19       Impact factor: 11.205

6.  Sex as a Biological Variable: A 5-Year Progress Report and Call to Action.

Authors:  Matthew E Arnegard; Lori A Whitten; Chyren Hunter; Janine Austin Clayton
Journal:  J Womens Health (Larchmt)       Date:  2020-01-22       Impact factor: 2.681

7.  Secular trends in the rates of preeclampsia, eclampsia, and gestational hypertension, United States, 1987-2004.

Authors:  Anne B Wallis; Audrey F Saftlas; Jason Hsia; Hani K Atrash
Journal:  Am J Hypertens       Date:  2008-03-13       Impact factor: 2.689

Review 8.  Considering sex as a biological variable in preclinical research.

Authors:  Leah R Miller; Cheryl Marks; Jill B Becker; Patricia D Hurn; Wei-Jung Chen; Teresa Woodruff; Margaret M McCarthy; Farida Sohrabji; Londa Schiebinger; Cora Lee Wetherington; Susan Makris; Arthur P Arnold; Gillian Einstein; Virginia M Miller; Kathryn Sandberg; Susan Maier; Terri L Cornelison; Janine A Clayton
Journal:  FASEB J       Date:  2016-09-28       Impact factor: 5.191

9.  Fetal fraction of cell free DNA in screening for hypertensive disorders at 11-13 weeks.

Authors:  Ioakeim Sapantzoglou; Margarita Gallardo Arozena; Vlad Dragoi; Ranjit Akolekar; Kypros H Nicolaides; Argyro Syngelaki
Journal:  J Matern Fetal Neonatal Med       Date:  2021-01-31

10.  Low fetal fraction in obese women at first trimester cell-free DNA based prenatal screening is not accompanied by differences in total cell-free DNA.

Authors:  Raj Shree; Teodora R Kolarova; Hayley J MacKinnon; Jaclynne M Hedge; Elena Vinopal; Kimberly K Ma; Christina M Lockwood; Suchitra Chandrasekaran
Journal:  Prenat Diagn       Date:  2021-08-14       Impact factor: 3.242

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.